News Releases | Insmed Incorporated

Month Year

Email Alerts

Oct 17, 2005

Insmed Submits Response to FDA Approvable Letter for iPlex

Read more
Sep 29, 2005

Insmed Issues Statement Regarding IPLEX(TM) Approvable Letter Press Release

Read more
Sep 29, 2005

Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary IGF-1 Deficiency

Read more
Sep 25, 2005

Insmed Receives Approvable Letter for iPlex(TM); Conference Call Tomorrow at 8:00am EST

Read more
Sep 24, 2005

Insmed Announces Appointment of Dr. Kenneth Attie; Former Genentech Researcher Assumes Role as Medical Director

Read more
Sep 19, 2005

SomatoKine(R) Pivotal Data to Be Featured in a Podium Presentation at the ESPE/LWPES 7th Joint Meeting of Pediatric Endocriniology in Lyon, France

Read more
Aug 8, 2005

Insmed Incorporated Reports Financial Results for the Second Quarter and First Half of 2005

Read more
Aug 2, 2005

Insmed to Release Second Quarter Financial Results; Monday, August 8

Read more
Jun 10, 2005

FDA Extends PDUFA Date for SomatoKine to October 03, 2005

Read more
May 31, 2005

Insmed Reports Detailed Positive Results from Its Pivotal Clinical Trial of SomatoKine in Patients with Growth Hormone Insensitivity Syndrome

Read more
May 25, 2005

Insmed to Present at Needham & Company Biotechnology Conference May 26, 2005

Read more
May 24, 2005

Insmed Announces the Continuation of Litigation in the United Kingdom; Judge's Ruling Allows for the Continuation of Legal Action in Suit Filed by Tercica

Read more
May 19, 2005

Insmed to Present at UBS Global Pharmaceutical Conference May 23, 2005

Read more
May 17, 2005

Insmed Announces Exclusive Option Agreement with UCSF for Series of IGF-1 Receptor Antagonists; Agreement Expands Collaboration on IGF-1 Program in Prostate Cancer

Read more
May 10, 2005

Insmed Incorporated Reports Financial Results for First Quarter of 2005

Read more
May 5, 2005

Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)

Read more
Apr 26, 2005

Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance

Read more
Apr 20, 2005

Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R)

Read more
Apr 18, 2005

Patent Infringement Suit Against Insmed Dismissed

Read more
Apr 13, 2005

FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome

Read more
Mar 16, 2005

Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004

Read more
Mar 15, 2005

Insmed to Release Fourth Quarter and Year End Financial Results; Wednesday, March 16

Read more
Mar 15, 2005

Insmed Announces Completion of $35 Million Financing

Read more
Mar 10, 2005

FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome

Read more
Feb 22, 2005

Insmed Provides Response to United States Patent Lawsuit; Seeks Immediate Dismissal or Summary Judgment for All Claims

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation

Download

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Press Releases

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Footer